<DOC>
	<DOCNO>NCT02517866</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety azilsartan medoxomil ( AZM ) Asian adult participant essential hypertension type 2 diabetes .</brief_summary>
	<brief_title>Azilsartan Medoxomil Treatment Essential Hypertension Type 2 Diabetes Asia</brief_title>
	<detailed_description>The drug test study call azilsartan medoxomil . Azilsartan medoxomil test treat people essential hypertension type 2 diabetes mellitus ( T2DM ) . This study look blood pressure people take azilsartan medoxomil addition standard care T2DM . The study enroll approximately 363 patient . All participant receive azilsartan medoxomil 40 mg tablet administer orally , day , 12 week . If participant 's blood pressure ( BP ) reach BP goal &lt; 140/85 mmHg week 6 , azilsartan medoxomil dose up-titrated 80 mg daily . All participant ask take one tablet time day throughout study . This multi-center trial conduct Asia . The overall time participate study 14 week . Participants make multiple visit clinic , contact 14 day last dose study drug follow-up assessment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>1 . In opinion investigator , participant capable understand comply protocol requirement . 2 . The participant , applicable , participant 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedure . 3 . Has type 2 diabetes mellitus ( T2DM ) essential hypertension . 4 . T2DM participant either treat stable life style intervention oral antidiabetic drug ( OADs ) stable , include dose adjustment within 12 week baseline . 5 . Is male female age 18 75 year , inclusive . 6 . Uncontrolled hypertension ( systolic blood pressure ≥140 mmHg &lt; 180 mmHg , diastolic blood pressure ≥85 mmHg &lt; 110 mmHg screen baseline . 7 . Has screening glycosylated hemoglobin ( HbA1C ) &lt; 9.5 % . 8 . Female participant must either nonchildbearing potential , ie , surgically sterilize ( define undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy ; tubal ligation alone consider sufficient ) one year last menstrual period ; , childbearing potential participant sexually active nonsterilized male partner , must agree use routinely adequate contraception signing inform consent throughout duration study . 1 . Has systolic blood pressure ≥140 mmHg diastolic blood pressure ≥90 mmHg despite concurrent treatment three antihypertensive medication different class adequate dos include diuretic . 2 . Has type 1 poorly control type 2 diabetes mellitus , define HbA1c ≥9.5 % screening . 3 . Is treated OADs stable treatment include dose change OADs least 12 week prior baseline . 4 . Has previously treat azilsartan medoxomil ( AZM ) azilsartan . 5 . Has secondary hypertension etiology ( eg , renovascular disease , pheochromocytoma , Cushing 's syndrome ) . 6 . Has congestive heart failure ( New York Heart Association class III IV ) , clinically relevant cardiac arrhythmia ( determined investigator 's clinical judgment participantbyparticipant basis ) , severe obstructive coronary artery disease . 7 . Has participate clinical trial include interventional observational study , receive investigational compound currently 30 day prior screen . 8 . Has severe renal impairment ( base estimate glomerular filtration rate [ GFR ] &lt; 30 mL/min/1.73m^2 ) Screening . 9 . Has hyperkalemia define serum potassium &gt; 5.0 mEq/L . 10 . Has alanine aminotransferase ( ALT ) level great 2.5 time upper limit normal , active liver disease , jaundice screening . 11 . Has clinically relevant disease ( eg malignancy , neurological , hepatic abnormality ) and/or significant abnormal laboratory finding ( past present ) , , opinion investigator , may put participant risk participation study . 12 . Is take prohibited medication include lithium aliskiren ( refer Edarbi® product insert ) . 13 . Has know hypersensitivity excipients angiotensin convert enzyme inhibitor ( ACEIs ) / angiotensin receptor blocker ( ARBs ) . 14 . Has prior angioedema due ACE inhibitor ARB . 15 . Breast feed pregnant woman woman intend become pregnant , within 1 month participate study ; intend donate ova time period , refusal submit urine test rule pregnancy prior enrolment end study . 16 . Have history alcohol abuse , drug abuse illegal drug addiction within 6 month prior sign inform consent . 17 . Is immediate family member , study site employee , dependent relationship study site employee involve conduct study ( eg , spouse , parent , child , sibling ) may consent duress .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Drug therapy</keyword>
</DOC>